IDRA21

Product Overview

IDRA-21 is a potent, investigational ampakine compound that acts as a positive allosteric modulator of the AMPA receptors in the brain. By enhancing excitatory neurotransmission, it significantly promotes long-term potentiation (LTP), making it a highly sought-after research ingredient for cognitive enhancement, memory optimization, and the development of therapeutics for age-related cognitive impairment.

Compared to first-generation ampakines (such as Aniracetam), IDRA-21 exhibits vastly superior efficacy, primarily due to its significantly longer half-life and extended duration of biological activity.

Technical Specifications (Certificate of Analysis)

Core Mechanism & Research Benefits

• AMPA Receptor Positive Modulation: IDRA-21 selectively targets and modulates AMPA receptors, increasing the strength of synaptic connections involved in learning and neuroplasticity.
• Advanced Cognitive Enhancement: Widely documented in preclinical research to dramatically improve memory retention, focus, and accelerated learning curves.
• Extended Half-Life Advantage: Offers sustained cognitive support with a prolonged window of activity, reducing the required dosing frequency compared to traditional, short-lived nootropic compounds.
• Neuroprotective Potential: Holds promising therapeutic implications for researching age-related cognitive decline, dementia, and brain barrier recovery pathways.

Storage & Commercial Applications

• Target Industries

Primarily utilized as an active ingredient in cognitive wellness research, neurological pharmaceutical development, and premium, high-end nootropic supplement formulations.

• Storage & Handling Conditions

Store in a tightly sealed container, protected from direct light, moisture, and heat. Keep at room temperature or in a cool, dry chemical storage environment to preserve maximum structural stability.